| Assay ID | Title | Year | Journal | Article |
|---|
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | | | |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
| High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7
| A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | | | |
| AID492575 | Inhibition of IKK-beta up to 8 uM | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID458028 | Inhibition of CYP3A4-mediated hydroxylation of testosterone in human liver microsomes in NADPH co-factor system by RP-HPLC | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID492594 | Protein binding in mouse plasma at 10 uM after 4 hrs by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492586 | Cytotoxicity against human Fa2N-4 cells after 24 hrs by ATP-lite 1-step assay | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492585 | Cytotoxicity against human HEK293 cells after 24 hrs by ATP-lite 1-step assay | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID458024 | Metabolic stability in human liver microsomes in UDPG co-factor system by RP-HPLC | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID492589 | Metabolic stability in human liver microsomes assessed as compound remaining at 1 uM after 1 hr by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492599 | Permeability at 50 uM at pH 6.2 by PAMPA | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492584 | Inhibition of CYP3A4 | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492604 | Aqueous solubility at pH 5 after 18 hrs by UV kinetic solubility method | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492577 | Inhibition of PKCbeta up to 8 uM | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492596 | Protein binding in human plasma at 10 uM after 4 hrs by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492600 | Aqueous solubility at pH 7.4 after 18 hrs by UV kinetic solubility method | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492578 | Drug level in mouse blood at 50 mg/kg, ip after 3 hrs by LC/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492595 | Protein binding in human plasma at 1 uM after 4 hrs by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID458027 | Metabolic stability in human liver S9 fraction in PAPS co-factor system by RP-HPLC | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID492576 | Inhibition of PKCtheta up to 8 uM | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID458021 | Inhibition of antigen receptor-mediated NF-kappaB activity in HEK293 cells after 2 hrs by luciferase reporter gene assay | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID458025 | Metabolic stability in human liver S9 fraction in UDPG co-factor system by RP-HPLC | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID492572 | Inhibition of JAK2 at 10 uM | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492588 | Metabolic stability in mouse liver microsomes assessed as compound remaining at 10 uM after 1 hr by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID458022 | Metabolic stability in human liver microsomes assessed as half life in NADPH co-factor system by RP-HPLC | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID492583 | Drug level in mouse blood at 10 mg/kg, ip after 0.5 hrs by LC/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492581 | Drug level in mouse blood at 30 mg/kg, ip after 0.5 hrs by LC/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492573 | Inhibition of TLK1 at 10 uM | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492601 | Aqueous solubility at pH 6.2 after 18 hrs by UV kinetic solubility method | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492603 | Inhibition of NF-kappaB activation transfected in PMA-stimulated HEK293 cells after 16 hrs by luciferase reporter gene assay | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID458023 | Metabolic stability in human liver S9 fraction assessed as half life in NADPH co-factor system by RP-HPLC | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID492587 | Metabolic stability in mouse liver microsomes assessed as compound remaining at 1 uM after 1 hr by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492590 | Metabolic stability in human liver microsomes assessed as compound remaining at 10 uM after 1 hr by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492598 | Permeability at 50 uM at pH 5 by PAMPA | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492602 | Inhibition of NF-kappaB activation transfected in TNF-alpha-stimulated HEK293 cells after 16 hrs by luciferase reporter gene assay | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID458026 | Metabolic stability in human liver microsomes in PAPS co-factor system by RP-HPLC | 2010 | Bioorganic & medicinal chemistry, Mar-01, Volume: 18, Issue:5
| Selective benzimidazole inhibitors of the antigen receptor-mediated NF-kappaB activation pathway. |
| AID492591 | Metabolic stability in mouse plasma assessed as compound remaining at 40 uM after 3 hrs by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492582 | Drug level in mouse blood at 10 mg/kg, ip after 3 hrs by LC/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492580 | Drug level in mouse blood at 30 mg/kg, ip after 3 hrs by LC/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492579 | Drug level in mouse blood at 50 mg/kg, ip after 0.5 hrs by LC/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492593 | Protein binding in mouse plasma at 1 uM after 4 hrs by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492592 | Metabolic stability in human plasma assessed as compound remaining at 40 uM after 3 hrs by LC/MS/MS analysis | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492597 | Permeability at 50 uM at pH 7.4 by PAMPA | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID492574 | Inhibition of raf kinase at 10 uM | 2010 | Journal of medicinal chemistry, Jun-24, Volume: 53, Issue:12
| Inhibition of protein kinase C-driven nuclear factor-kappaB activation: synthesis, structure-activity relationship, and pharmacological profiling of pathway specific benzimidazole probe molecules. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
| Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
| A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
| Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | 2014 | Journal of biomolecular screening, Jul, Volume: 19, Issue:6
| A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum. |
| AID1794808 | Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL). | | | |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |